Across TCGA pan-cancer cohorts, POLG2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated POLG2 data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher POLG2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POLG2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LUAD and UCEC are the cancer types where POLG2 Mutation most reproducibly stratifies survival.